12.50
Ocular Therapeutix Inc stock is traded at $12.50, with a volume of 2.97M.
It is up +4.17% in the last 24 hours and up +29.94% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$12.00
Open:
$12
24h Volume:
2.97M
Relative Volume:
1.30
Market Cap:
$1.99B
Revenue:
$61.10M
Net Income/Loss:
$-138.36M
P/E Ratio:
-9.2593
EPS:
-1.35
Net Cash Flow:
$-90.59M
1W Performance:
+7.20%
1M Performance:
+29.94%
6M Performance:
+63.61%
1Y Performance:
+58.43%
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
OCUL
Ocular Therapeutix Inc
|
12.50 | 1.91B | 61.10M | -138.36M | -90.59M | -1.35 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-08-25 | Initiated | William Blair | Outperform |
Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
Mar-11-25 | Initiated | Needham | Buy |
Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
May-31-24 | Resumed | Piper Sandler | Overweight |
Feb-09-24 | Initiated | BofA Securities | Buy |
Apr-21-23 | Initiated | Robert W. Baird | Outperform |
Aug-10-22 | Resumed | Berenberg | Buy |
Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
Dec-17-20 | Initiated | Berenberg | Buy |
Nov-13-20 | Reiterated | Raymond James | Strong Buy |
Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
May-21-19 | Reiterated | H.C. Wainwright | Buy |
May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
Nov-15-18 | Initiated | Raymond James | Strong Buy |
Sep-07-18 | Initiated | Piper Jaffray | Overweight |
Oct-24-17 | Initiated | Guggenheim | Buy |
Jul-26-17 | Initiated | H.C. Wainwright | Buy |
Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
Ocular Therapeutix stock hits 52-week high at 12.38 USD - Investing.com
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2025 Earnings Call Transcript - Insider Monkey
Ocular Therapeutix: Q2 Earnings Snapshot - Huron Daily Tribune
Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial Strength - GuruFocus
Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Ocular Therapeutix 2025 Q2 Earnings Deepening Losses Amid Strategic Momentum - AInvest
Ocular Therapeutix Reports Second Quarter 2025 Financial Results - VisionMonday.com
Ocular Therapeutix Reports Q2 2025 Financial Results - TipRanks
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
OCUL Sales Drop 18% - The Motley Fool
Ocular Therapeutix Earnings Call: Positive Outlook Amid Trial Progress - TipRanks
Ocular Therapeutix Q2 2025: Unpacking Key Contradictions in SOL-R Trial Criteria and FDA Relations - AInvest
Ocular Therapeutix stock maintains Buy rating at TD Cowen ahead of Phase III data - Investing.com Canada
Ocular Therapeutix Q2 2025 Earnings Call Transcript - MarketBeat
Clear Street reiterates Buy rating on Ocular Therapeutix stock at $18 - Investing.com Canada
Raymond James reiterates Strong Buy on Ocular Therapeutix stock with $19 target - Investing.com Canada
Earnings call transcript: Ocular Therapeutix misses Q2 2025 earnings, stock drops - Investing.com
Ocular Therapeutix Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ocular Therapeutix tumbles as Q2 results miss estimates - Investing.com
Ocular Therapeutix: Can AXPAXLI's Pipeline Offset Financial Headwinds? - AInvest
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Ocular Therapeutix Inc earnings missed by $0.04, revenue fell short of estimates - Investing.com
Ocular Therapeutix Reports Second Quarter 2025 Financial Results and Business Highlights - TradingView
Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights - The Manila Times
OCULAR THERAPEUTIX, INC SEC 10-Q Report - TradingView
Ocular Therapeutix raises $97mln, expects cash runway into 2028. - AInvest
What's Next: Ocular Therapeutix's Earnings Preview - 富途牛牛
Ocular Therapeutix stock maintains Strong Buy rating at Raymond James By Investing.com - Investing.com Canada
Ocular Therapeutix Inc (OCUL) Q2 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
What analysts say about Ocular Therapeutix Inc. stockBuild wealth with high-performing stocks - Jammu Links News
Is Ocular Therapeutix Inc. a growth stock or a value stockHigh-yield investments - Jammu Links News
When is Ocular Therapeutix Inc. stock expected to show significant growthAchieve impressive returns with smart timing - Jammu Links News
What are the latest earnings results for Ocular Therapeutix Inc.Capitalize on market shifts with expert advice - Jammu Links News
How does Ocular Therapeutix Inc. compare to its industry peersBreakout stock performance - Jammu Links News
How does Ocular Therapeutix Inc. generate profit in a changing economyInvest confidently with data-backed picks - Jammu Links News
Is it the right time to buy Ocular Therapeutix Inc. stockTriple-digit growth rates - Jammu Links News
Should I hold or sell Ocular Therapeutix Inc. stock in 2025Capitalize on market trends with expert guidance - Jammu Links News
How volatile is Ocular Therapeutix Inc. stock compared to the marketBuild a diversified portfolio for steady profits - Jammu Links News
What are Ocular Therapeutix Inc. company’s key revenue driversGet daily updates on top-performing stocks - Jammu Links News
Is Ocular Therapeutix Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - Jammu Links News
What is Ocular Therapeutix Inc. company’s growth strategyAchieve rapid portfolio appreciation - Jammu Links News
How strong is Ocular Therapeutix Inc. company’s balance sheetExtraordinary performance - Jammu Links News
Does Ocular Therapeutix Inc. stock perform well during market downturnsLow Risk Guidance That Work - jammulinksnews.com
Identifying reversal signals in Ocular Therapeutix Inc.Watchlist for Low Risk High Return Stocks Updated - metal.it
Using data filters to optimize entry into Ocular Therapeutix Inc.Risk Managed Intraday Trade Alerts Increase in Volume - metal.it
Quantitative breakdown of Ocular Therapeutix Inc. recent moveReliable Alerts for Daily Stock Movers Released - metal.it
Ocular Therapeutix Inc. Reaches Critical Trendline SupportTrend Analysis for Safer Trades Gains Popularity - metal.it
Can Ocular Therapeutix Inc. Rally Enough to Break EvenTechnical Entry Strategy for Beginners Explained - metal.it
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025 - GlobeNewswire
After Leaping 31% Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Are Not Flying Under The Radar - simplywall.st
Ocular Therapeutix Sets Q2 Earnings Date: Key Retina Biotech Updates Coming August 5 - Stock Titan
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):